HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Humacyte, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.40−0.03 (-6.50%)

Close on Oct 19, 2026

Market cap: $93.93M
P/E (TTM): –
Dividend yield: –

Dividends

Humacyte has not reported a dividend

No dividend per share appears in Humacyte's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Humacyte's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 15, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HUMA.

Revenue growth159.3% · median -4.2%

Gross margin-494.6% · median 44.6%

Operating margin-5240.8% · median -1334.7%

Net margin-4560.8% · median -1272.5%

Company	Revenue	Growth
ELUT	$12.14M	-0.3%
DYAI	$3.80M	-8.0%
HUMA	$2.12M	+159.3%
PLUR	$1.02M	-24.0%
PROK	$818.00K	+55.2%
PRME	–	–

Company

Next earnings (est.): Nov 11, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 184
Held by institutions: 26.4%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1818382

Advertisement
300 × 250